Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors

NCT05150691 is registered in ClinicalTrials.gov with DualityBio Inc. as lead sponsor.

NCT NCT05150691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05150691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors
Lead sponsor
DualityBio Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 31, 2022
Completion date
October 31, 2027
Enrollment
796 (estimated)
Sites
102

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive advanced solid tumor